Emil Novo Nordisk - Search News

Novo Nordisk Skeptic Finally Upgrades Stock

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

Markets Insider · 11h

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Bloomberg L.P. · 14h

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

3don MSN

Novo Nordisk shares fall on weight-loss drug trial

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

1don MSN

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk Skeptic Finally Upgrades Stock

Trending now